ArticleBMC gastroenterology2024

Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.

Ji Eun Na et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.